Man smiling behind laptop)

CSL Behring Newsroom

Recent News Releases

CSL Behring Hosts Symposium on Managing CIDP with Immunoglobulin, Supports 14 Scientific Posters and Two Oral Presentations at the 2018 Peripheral Nerve Society Annual Meeting
20 Jul 2018 News Release

• Presentations include new analysis from the PATH trial, the largest clinical trial in CIDP

• CSL Behring is now the only company to offer a portfolio of biologics to address the unique needs of CIDP patients in the US – Hizentra®, the first and only subcutaneous immunoglobulin option for CIDP patients, and Privigen®, the No.1 intravenous immunoglobulin used in U.S. hospitals

CSL Behring, Leader in Rare Diseases, Hosts a Symposium on CIDP, Presents 7 Poster Sessions Featuring PATH Study Data at the 15th International Congress on Neuromuscular Diseases
05 Jul 2018 News Release

- CSL Behring hosts symposium featuring patient perspective on subcutaneous immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment

- CSL Behring offers a portfolio of immunoglobulin therapies to address the unique needs of CIDP patients – Hizentra®, the first and only subcutaneous immunoglobulin option for CIDP patients and Privigen®, approved for treating CIDP since 2013

A New Generation of Coagulation Specialists is Advancing Research with Support From CSL Behring Global Grant
22 Jun 2018 News Release

Named after coagulation therapy pioneer Prof. Norbert Heimburger, the grant has been awarded this year to researchers from France, Netherlands and the United States.

CSL Behring Presents New Data on Subcutaneous Immunoglobulin Treatment from the Largest CIDP Study, the PATH Trial, at the 4th Congress of the European Academy of Neurology
15 Jun 2018 News Release

- CSL Behring offers a portfolio of immunoglobulin therapies to address the unique needs of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients
- CSL Behring will support an oral presentation and four ePresentations focusing on CIDP treatment during the EAN congress

IDELVION® Newly Approved 3500 IU Vial to Provide Convenience to Patients Using Larger Volumes
31 May 2018 News Release

• IDELVION 14-day dosing option for some patients, combined with the larger vial size, will improve convenience with fewer vials and less infusions
• New vial option delivers on CSL Behring’s promise to enhance current treatments and provide more alternatives to patients

Hemophilia Association of New Jersey Recognizes CSL CEO Paul Perreault as “Humanitarian Man of the Year”
14 May 2018 News Release

HANJ President David Lechner presented the award to Perreault at the association’s 38th Annual Testimonial Dinner Dance

Want to know more about how we are sharing stories of biotech's promise?

Read Vita

CSL Behring Media Contacts

Natalie de Vane

Corporate Inquiries
Phone: +1 610-878-4468

Greg Healy

Product Inquiries
(Bleeding disorders and Warfarin reversal)
Phone: +1 610-878-4841

Christopher Florentz

Corporate Inquiries
Phone: +1 610-878-4316

Jennifer Purdue

Product Inquiries
(Immune disorders, Alpha-1, HAE)
Phone: +1 610-878-4802

CSL Behring Production Sites

Sandra Ruckstuhl

Bern, Switzerland
Phone: +41 31-344-1124

Maureen E. Powell

Kankakee, Illinois, USA
Phone: +1 815-935-3120

Stephanie Fuchs

Marburg, Germany
Phone: +49 6421 39-5972

Christina Hickie

Broadmeadows, Victoria, Australia
Phone: +61 429 609 762

Past News Releases by Year

News Archives 2016 pdf
News Archives 2015 pdf
News Archives 2014  pdf
News Archives 2013  pdf
News Archives 2012  pdf

Get our latest Vita stories in your inbox

mail@example.com
First name
Last name
Country

Thanks!

You have now been added
to the CSL Behring Vita list